Meesho's zero-commission model scales to 264 Mn users as Snapdeal faces Supreme Court drug-sale case
Weekly Inc42 roundup: Meesho leans on zero-commission listings and in-house logistics arm Valmo to grow annual transacting users to 264 Mn, while rival marketplace Snapdeal battles a Supreme Court case over unlicensed drug sales on its platform.
What happened
Weekly Inc42 roundup covers Meesho's zero-commission ecommerce model and Valmo logistics, plus Snapdeal's Supreme Court legal case over unlicensed drug sale on
Key facts
- 264 Mn annual transacting users
Why this matters
Meesho's scale and logistics integration (Valmo) make it a strengthening competitive anchor in Indian ecommerce, while Snapdeal's legal overhang could reshape marketplace consolidation or divestiture dynamics in the sector.
What to watch
- Supreme Court ruling on marketplace liability for third-party drug sales
- Meesho DRHP filing or funding round with unit economics disclosure
- Valmo's cost-per-shipment trend vs GMV growth
- Any regulatory notice to Meesho/other platforms following Snapdeal precedent
- Track Meesho's next funding/IPO disclosure for revenue-per-user and Valmo margin data
- Monitor Supreme Court hearing dates and any interim compliance orders affecting marketplace liability
- Watch for competitor (Flipkart Shopsy, Amazon Bazaar) response to Meesho's zero-commission user growth
- Check seller sentiment/attrition data on Meesho given rising logistics dependency on Valmo
Also reported by
- Inc42 — Same time